Shield Therapeutics names new chief financial officer
Hans-Peter Rudolf is a Swiss national with extensive international experience, particularly in the US.
Company
Shield Therapeutics PLC
LON:STX
Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer ® /Feraccru ® (ferric maltol). The group has launched Accrufer® in the US and Feraccru ® is commercialized in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical for the development and commercialization of Accrufer ® / Feraccru ® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co in the Republic of Korea, and with KYE Pharmaceuticals in Canada.
175 stories · page 5 of 9
Shield Therapeutics fundraise totals £29.2mln as open offer oversubscribed
“We will be continuing to develop our launch plans for Accrufer in the United States"
Shield Therapeutics PLC takes bold approach in the US
Below we take a closer look at Shield Therapeutics...
Shield Therapeutics receives Australian regulatory green light for iron deficiency drug
The product has already been approved in the UK, European Union, Switzerland and the United States
Shield Therapeutics raises £25mln for US launch of Accrufer
Sales might exceed US$100mln from the third year according to forecasts
Shield Therapeutics receives additional support from shareholder loans
The pharmaceuticals firm said AOP Orphan International AG and board member Christian Schweiger have stated that they would be prepared to collectively lend the group up to £4.4mln
Archive
Small Cap Wrap - Urban Logistics REIT, Oracle Power, Star Phoenix and more...
Cornish Metals (TSX-V: CUSN) intends to list on AIM. The Company is proposing to raise £5 million by way of private placement of new Common Shares (the “Fundraising”) to advance the United Downs copper-tin project. The Company expects that
Shield Therapeutics CEO hails positive year as European sales grow 70%
“We aim to give clarity on the US by the end of March and I am sure that 2021 will be a transformational year for Shield," said Tim Watts
Shield Therapeutics updates on commercialisation efforts for Accrufer in the US
The company said it has received numerous indicative proposals from potential commercialisation partners, adding that COVID-19 has accentuated Accrufer as an iron deficiency treatment
Shield Therapeutics says TEVA has withdrawn patent challenge
Shield’s general counsel, Lucy Huntington-Bailey, said: "We are delighted that the European Patent Office has decided not to continue proceedings following the withdrawal of the opposition by TEVA and saw no reason to amend the patent as or
Shield Therapeutics confident of securing a US deal this year as profits return
The profit followed an US$11.4mln upfront payment from ASK Pharm, the group's partner in China
Shield Therapeutics strongly supported for commercialisation, pricing of Feraccru after new data, says analyst
A licensing deal in the US, where it would be called Accrufer, can start to unlock the world’s largest iron replacement market
Shield Therapeutics supported in negotiations with prospective US partners by new findings, says Peel Hunt
Analysts say completing the negotiations represents significant further upside potential for the company
Shield Therapeutics soars as reanalysis of Feraccru study finds positive results
"We are very pleased that the reanalysis of the AEGIS-H2H study data demonstrates that Feraccru/Accrufer is a credible alternative to IV therapy and offers economic advantages,” said Tim Watts.
Shield Therapeutics to take kidney disease treatment forward to phase III study
Hyperphosphatemia is a condition where due to renal failure there is too much phosphorus present in the blood
Shield Therapeutics brings co-founder Christian Schweiger back onto the board
The iron deficiency specialist said he has "substantial experience working with both large and small pharmaceutical companies"
Shield Therapeutics notes publications concerning Feraccru/Accrufer product
One study concluded that ferric maltol, a component of Feraccru/Accrufer, was “well tolerated” by patients suffering from pulmonary hypertension and resulted in “significant improvements in iron status and haemoglobin levels"
Shield Therapeutics announces appointment of Hans Peter Hasler as its non-executive chairman from June 18
The group announced on May 21 that its current chairman, James Karis would not seek re-election and would be stepping down at the AGM
Shield Therapeutics CEO says finding a US partner for lead drug is "top priority" for 2020
Tim Watts' comment was made alongside the company’s 2019 results, which charted a period of significant progress
Shield Therapeutics says plenty of interest from potential US partners for iron deficiency treatment
Sales of Feraccru in Germany and the UK rose during the first quarter of 2020 according to European partner Norgine